nach oben

Internal and Emergency Medicine

Erschienen in:

06.12.2018 | IM - REVIEW

Triggering agents and microbiome as environmental factors on Behçet’s syndrome

verfasst von: Gonca Mumcu, Haner Direskeneli

Erschienen in: Internal and Emergency Medicine | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Abstract

Environmental and other triggering factors are suggested to cause the onset and the clinical relapses of Behçet’s syndrome (BS), a multi-systemic inflammatory disorder. In this review, environmental factors are discussed according to their interactions with etiopathogenesis, immune response and disease activity. Stress is a common self-triggering factor for most BS patients. Stimuli such as some foods can activate oral ulcers, and may be linked to the histamine content of the food. Oral/skin trauma and menstruation associated with hormonal factors aggravate, whereas allergy/atopy seem to alleviate the symptoms of BS. Infections are associated with BS, and microbial stimuli can activate inflammation in mucosal surfaces with increased Th1/Th17 responses. Fecal and oral microbiome patterns change in diversity and composition in BS. Better oral hygiene applications and anti-microbial interventions might be helpful to suppress oral ulcers in BS.

Yazici H, Seyahi E, Hatemi G, Yazici Y (2018) Behcet syndrome: a contemporary view. Nat Rev Rheumatol 14(2):107–119. https://doi.org/10.1038/nrrheum.2017.208 CrossRefPubMed

McGonagle D, Aydin SZ, Gul A, Mahr A, Direskeneli H (2015) ‘MHC-I-opathy’-unified concept for spondyloarthritis and Behcet disease. Nat Rev Rheumatol 11(12):731–740. https://doi.org/10.1038/nrrheum.2015.147 CrossRefPubMed

Direskeneli H (2006) Autoimmunity vs autoinflammation in Behcet’s disease: do we oversimplify a complex disorder? Rheumatology (Oxford) 45(12):1461–1465CrossRef

Gul A (2015) Pathogenesis of Behcet’s disease: autoinflammatory features and beyond. Semin Immunopathol 37(4):413–418. https://doi.org/10.1007/s00281-015-0502-8 CrossRefPubMed

Direskeneli H (2001) Behcet’s disease: infectious aetiology, new autoantigens, and HLA-B51. Ann Rheum Dis 60(11):996–1002CrossRefPubMedPubMedCentral

Anaya JM, Restrepo-Jimenez P, Ramirez-Santana C (2018) The autoimmune ecology: an update. Curr Opin Rheumatol 30(4):350–360. https://doi.org/10.1097/BOR.0000000000000498 CrossRefPubMed

Ozen S, Demirkaya E, Amaryan G, Kone-Paut I, Polat A, Woo P, Uziel Y, Modesto C, Finetti M, Quartier P, Papadopoulou-Alataki E, Al-Mayouf SM, Fabio G, Gallizzi R, Cantarini L, Frenkel J, Nielsen S, Hofer M, Insalaco A, Acikel C, Ozdogan H, Martini A, Ruperto N, Gattorno M, Paediatric Rheumatology International Trials O, Eurofever P (2014) Results from a multicentre international registry of familial Mediterranean fever: impact of environment on the expression of a monogenic disease in children. Ann Rheum Dis 73(4):662–667. https://doi.org/10.1136/annrheumdis-2012-202708 CrossRefPubMed

Bergmeier LA (2018) Oral mucosa in health and disease: a concise handbook. Springer, BerlinCrossRef

Alpsoy E (2016) Behcet’s disease: a comprehensive review with a focus on epidemiology, etiology and clinical features, and management of mucocutaneous lesions. J Dermatol 43(6):620–632. https://doi.org/10.1111/1346-8138.13381 CrossRefPubMed

10.

Mumcu G, Sur H, Inanc N, Karacayli U, Cimilli H, Sisman N, Ergun T, Direskeneli H (2009) A composite index for determining the impact of oral ulcer activity in Behcet’s disease and recurrent aphthous stomatitis. J Oral Pathol Med 38(10):785–791. https://doi.org/10.1111/j.1600-0714.2009.00803.x CrossRefPubMed

11.

Soy M, Erken E, Konca K, Ozbek S (2000) Smoking and Behcet’s disease. Clin Rheumatol 19(6):508–509CrossRefPubMed

12.

Iris M ÖE, Aksoy A, Alibaz-Öner F, Inanc N, Ergun T, Direskeneli H, Mumcu G (2018) The assessment of contributing factors to oral ulcer presence in Behçet’s disease: Dietary and non-dietary factors. Eur J Rheumatol 5:240–243. https://doi.org/10.5152/eurjrheum.2018.18094 CrossRefPubMedPubMedCentral

13.

Verschuere S, Bracke KR, Demoor T, Plantinga M, Verbrugghe P, Ferdinande L, Lambrecht BN, Brusselle GG, Cuvelier CA (2011) Cigarette smoking alters epithelial apoptosis and immune composition in murine GALT. Lab Invest 91(7):1056–1067. https://doi.org/10.1038/labinvest.2011.74 CrossRefPubMed

14.

Alibaz-Oner F, Mumcu G, Kubilay Z, Ozen G, Celik G, Karadeniz A, Can M, Oner SY, Inanc N, Atagunduz P, Ergun T, Direskeneli H (2014) Unmet need in Behcet’s disease: most patients in routine follow-up continue to have oral ulcers. Clin Rheumatol 33(12):1773–1776. https://doi.org/10.1007/s10067-014-2585-3 CrossRefPubMed

15.

Volle G, Fraison JB, Gobert D, Goulenok T, Dhote R, Fain O, Gonzalez-Chiappe S, Lhote F, Papo T, Thuillier A, Riviere S, Mahr A (2017) Dietary and nondietary triggers of oral ulcer recurrences in Behcet’s disease. Arthritis Care Res (Hoboken) 69(9):1429–1436. https://doi.org/10.1002/acr.23155 CrossRef

16.

Ilhan B, Can M, Alibaz-Oner F, Yilmaz-Oner S, Polat-Korkmaz O, Ozen G, Mumcu G, Maradit Kremers H, Direskeneli H (2016) Fatigue in patients with Behcet’s syndrome: relationship with quality of life, depression, anxiety, disability and disease activity. Int J Rheum Dis. https://doi.org/10.1111/1756-185x.12839 CrossRefPubMed

17.

Buyuktas D, Hatemi G, Yuksel-Findikoglu S, Ugurlu S, Yazici H, Yurdakul S (2015) Fatigue is correlated with disease activity but not with the type of organ involvement in Behcet’s syndrome: a comparative clinical survey. Clin Exp Rheumatol 33(6 Suppl 94):S107–S112PubMed

18.

Grayson PC, Amudala NA, McAlear CA, Leduc RL, Shereff D, Richesson R, Fraenkel L, Merkel PA (2013) Illness perceptions and fatigue in systemic vasculitis. Arthritis Care Res (Hoboken) 65(11):1835–1843. https://doi.org/10.1002/acr.22069 CrossRef

19.

Melikoglu M, Melikoglu MA (2013) The prevalence of fibromyalgia in patients with Behcet’s disease and its relation with disease activity. Rheumatol Int 33(5):1219–1222. https://doi.org/10.1007/s00296-012-2530-1 CrossRefPubMed

20.

Scherrer MAR, Rocha VB, Garcia LC (2017) Behcet’s disease: review with emphasis on dermatological aspects. An Bras Dermatol 92(4):452–464. https://doi.org/10.1590/abd1806-4841.20177359 CrossRefPubMedPubMedCentral

21.

Alpsoy E, Akman A (2009) Behcet’s disease: an algorithmic approach to its treatment. Arch Dermatol Res 301(10):693–702. https://doi.org/10.1007/s00403-009-0990-2 CrossRefPubMed

22.

Sakane T, Takeno M, Suzuki N, Inaba G (1999) Behcet’s disease. N Engl J Med 341(17):1284–1291. https://doi.org/10.1056/NEJM199910213411707 CrossRefPubMed

23.

Wakabayashi T, Morimura Y, Miyamoto Y, Okada AA (2003) Changing patterns of intraocular inflammatory disease in Japan. Ocul Immunol Inflamm 11(4):277–286CrossRefPubMed

24.

Yoshida A, Kawashima H, Motoyama Y, Shibui H, Kaburaki T, Shimizu K, Ando K, Hijikata K, Izawa Y, Hayashi K, Numaga J, Fujino Y, Masuda K, Araie M (2004) Comparison of patients with Behcet’s disease in the 1980s and 1990s. Ophthalmology 111(4):810–815. https://doi.org/10.1016/j.ophtha.2003.07.018 CrossRefPubMed

25.

Kitamei H, Kitaichi N, Namba K, Kotake S, Goda C, Kitamura M, Miyazaki A, Ohno S (2009) Clinical features of intraocular inflammation in Hokkaido, Japan. Acta Ophthalmol 87(4):424–428. https://doi.org/10.1111/j.1755-3768.2008.01282.x CrossRefPubMed

26.

Ideguchi H, Suda A, Takeno M, Ueda A, Ohno S, Ishigatsubo Y (2011) Behçet disease: evolution of clinical manifestations. Medicine (Baltimore) 90(2):125–132CrossRef

27.

Kim DY, Choi MJ, Cho S, Kim DW, Bang D (2014) Changing clinical expression of Behcet disease in Korea during three decades (1983–2012): chronological analysis of 3674 hospital-based patients. Br J Dermatol 170(2):458–461. https://doi.org/10.1111/bjd.12661 CrossRefPubMed

28.

Lee YB, Lee SY, Choi JY, Lee JH, Chae HS, Kim JW, Han KD, Park YG, Yu DS (2018) Incidence, prevalence, and mortality of Adamantiades-Behcet’s disease in Korea: a nationwide, population-based study (2006–2015). J Eur Acad Dermatol Venereol 32(6):999–1003. https://doi.org/10.1111/jdv.14601 CrossRefPubMed

29.

Direskeneli H, Mumcu G (2010) A possible decline in the incidence and severity of Behcet’s disease: implications for an infectious etiology and oral health. Clin Exp Rheumatol 28(4 Suppl 60):S86–S90PubMed

30.

Horie Y, Kitaichi N, Hijioka K, Sonoda KH, Saishin Y, Kezuka T, Goto H, Takeuchi M, Nakamura S, Kimoto T, Shimakawa M, Kita M, Sugita S, Mochizuki M, Hori J, Iwata M, Shoji J, Fukuda M, Kaburaki T, Numaga J, Kawashima H, Fukushima A, Joko T, Takai N, Ozawa Y, Meguro A, Mizuki N, Namba K, Ishida S, Ohno S (2016) Ocular Behcet’s disease is less complicated with allergic disorders. A nationwide survey in Japan. Clin Exp Rheumatol 34(6 Suppl 102):111–114PubMed

31.

Karacayli U, Mumcu G, Simsek I, Pay S, Kose O, Erdem H, Direskeneli H, Gunaydin Y, Dinc A (2009) The close association between dental and periodontal treatments and oral ulcer course in behcet’s disease: a prospective clinical study. J Oral Pathol Med 38(5):410–415. https://doi.org/10.1111/j.1600-0714.2009.00765.x CrossRefPubMed

32.

van de Ree-Pellikaan C, Kiewiet-Kemper RM, Tchetverikov I, Westerweel PE (2016) Oral ulcerations after placement of orthodontic braces and skin pustules after laser hair removal: novel inducers of pathergy reactions in new-onset Behçet’s disease. BMJ Case Rep. https://doi.org/10.1136/bcr-2014-209208 CrossRefPubMedPubMedCentral

33.

Mizushima Y, Matsuda T, Hoshi K, Ohno S (1988) Induction of Behcet’s disease symptoms after dental treatment and streptococcal antigen skin test. J Rheumatol 15(6):1029–1030PubMed

34.

Choi S-MCY-J, Kim J-T, Lee S-H, Park M-S, Kim B-C, Kim M-K, Cho K-H, Acikel C (2010) A case of recurrent neuro-Behçet’s disease after tooth extraction. J Korean Med Sci 25:185–187CrossRefPubMed

35.

Dilsen N, Konice M, Aral O, Ocal L, Inanc M, Gul A (1993) Comparative study of the skin pathergy test with blunt and sharp needles in Behcet’s disease: confirmed specificity but decreased sensitivity with sharp needles. Ann Rheum Dis 52(11):823–825CrossRefPubMedPubMedCentral

36.

Perricone C, Versini M, Ben-Ami D, Gertel S, Watad A, Segel MJ, Ceccarelli F, Conti F, Cantarini L, Bogdanos DP, Antonelli A, Amital H, Valesini G, Shoenfeld Y (2016) Smoke and autoimmunity: the fire behind the disease. Autoimmun Rev 15(4):354–374. https://doi.org/10.1016/j.autrev.2016.01.001 CrossRefPubMed

37.

Tuzun B, Wolf R, Tuzun Y, Serdaroglu S (2000) Recurrent aphthous stomatitis and smoking. Int J Dermatol 39(5):358–360CrossRefPubMed

38.

Malek Mahdavi A, Khabbazi A, Yaaghoobian B, Ghojazadeh M, Agamohammadi R, Kheyrollahiyan A, Rashtchizadeh N (2018) Cigarette smoking and risk of Behcet’s disease: a propensity score matching analysis. Mod Rheumatol. https://doi.org/10.1080/14397595.2018.1493065 CrossRefPubMed

39.

Kalayciyan A, Orawa H, Fimmel S, Perschel FH, Gonzalez JB, Fitzner RG, Orfanos CE, Zouboulis CC (2007) Nicotine and biochanin A, but not cigarette smoke, induce anti-inflammatory effects on keratinocytes and endothelial cells in patients with Behcet’s disease. J Invest Dermatol 127(1):81–89. https://doi.org/10.1038/sj.jid.5700492 CrossRefPubMed

40.

Ciancio G, Colina M, La Corte R, Lo Monaco A, De Leonardis F, Trotta F, Govoni M (2010) Nicotine-patch therapy on mucocutaneous lesions of Behcet’s disease: a case series. Rheumatology (Oxford) 49(3):501–504. https://doi.org/10.1093/rheumatology/kep401 CrossRef

41.

Hill SC, Stavrakoglou A, Coutts IR (2010) Nicotine replacement therapy as a treatment for complex aphthosis. J Dermatol Treat 21(5):317–318. https://doi.org/10.3109/09546630903271563 CrossRef

42.

Ozer HT, Gunesacar R, Dinkci S, Ozbalkan Z, Yildiz F, Erken E (2012) The impact of smoking on clinical features of Behcet’s disease patients with glutathione S-transferase polymorphisms. Clin Exp Rheumatol 30(3 Suppl 72):S14–S17PubMed

43.

Pandey A, Garg J, Krishnamoorthy P, Palaniswamy C, Doshi J, Lanier G, Ahmad H (2014) Predictors of coronary artery disease in patients with Behcet’s disease. Cardiology 129(4):203–206. https://doi.org/10.1159/000365139 CrossRefPubMed

44.

Chang HK, Lee SS, Kim JW, Jee YK, Kim JU, Lee YW, Yoon BY (2003) The prevalence of atopy and atopic diseases in Behcet’s disease. Clin Exp Rheumatol 21(4 Suppl 30):S31–S34PubMed

45.

Yazici A, Orge Gonullu E, Kardes B, Cefle A (2013) The prevalence of atopy in patients with familial Mediterranean fever and Behcet’s disease. Clin Exp Rheumatol 31(3 Suppl 77):68–70PubMed

46.

Dhuban KB, d’Hennezel E, Ben-Shoshan M, McCusker C, Clarke A, Fiset P, Mazer B, Piccirillo CA (2013) Altered T helper 17 responses in children with food allergy. Int Arch Allergy Immunol 162(4):318–322. https://doi.org/10.1159/000354028 CrossRefPubMed

47.

Fattahi F, Brandsma CA, Lodewijk M, Reinders-Luinge M, Postma DS, Timens W, Hylkema MN, Ten Hacken NH (2016) Atopy and inhaled corticosteroid use associate with fewer IL-17 + cells in asthmatic airways. PLoS One 11(8):e0161433. https://doi.org/10.1371/journal.pone.0161433 CrossRefPubMedPubMedCentral

48.

Yavuz S, Ozilhan G, Elbir Y, Tolunay A, Eksioglu-Demiralp E, Direskeneli H (2007) Activation of neutrophils by testosterone in Behcet’s disease. Clin Exp Rheumatol 25(4 Suppl 45):S46–S51PubMed

49.

Yavuz S, Akdeniz T, Hancer V, Bicakcigil M, Can M, Yanikkaya-Demirel G (2016) Dual effects of testosterone in Behcet’s disease: implications for a role in disease pathogenesis. Genes Immun 17(6):335–341. https://doi.org/10.1038/gene.2016.28 CrossRefPubMed

50.

Nowak J, Borkowska B, Pawlowski B (2016) Leukocyte changes across menstruation, ovulation, and mid-luteal phase and association with sex hormone variation. Am J Hum Biol 28(5):721–728. https://doi.org/10.1002/ajhb.22856 CrossRefPubMed

51.

Guzelant G, Ozguler Y, Esatoglu SN, Karatemiz G, Ozdogan H, Yurdakul S, Yazici H, Seyahi E (2017) Exacerbation of Behcet’s syndrome and familial Mediterranean fever with menstruation. Clin Exp Rheumatol 35(Suppl 108 6):95–99PubMed

52.

Coit P, Mumcu G, Ture-Ozdemir F, Unal AU, Alpar U, Bostanci N, Ergun T, Direskeneli H, Sawalha AH (2016) Sequencing of 16S rRNA reveals a distinct salivary microbiome signature in Behcet’s disease. Clin Immunol 169:28–35. https://doi.org/10.1016/j.clim.2016.06.002 CrossRefPubMed

53.

Mumcu G, Inanc N, Yavuz S, Direskeneli H (2007) The role of infectious agents in the pathogenesis, clinical manifestations and treatment strategies in Behcet’s disease. Clin Exp Rheumatol 25(4 Suppl 45):S27–S33PubMed

54.

Mumcu G, Ergun T, Inanc N, Fresko I, Atalay T, Hayran O, Direskeneli H (2004) Oral health is impaired in Behcet’s disease and is associated with disease severity. Rheumatology (Oxford) 43(8):1028–1033CrossRef

55.

Mumcu G (2008) Behcet’s disease: a dentist’s overview. Clin Exp Rheumatol 26(4 Suppl 50):S121–S124PubMed

56.

Mumcu G, Inanc N, Aydin SZ, Ergun T, Direskeneli H (2009) Association of salivary S. mutans colonisation and mannose-binding lectin deficiency with gender in Behcet’s disease. Clin Exp Rheumatol 27(2 Suppl 53):S32–S36PubMed

57.

Mumcu G, Ergun T, Elbir Y, Eksioglu-Demiralp E, Yavuz S, Atalay T, Direskeneli H (2005) Clinical and immunological effects of azithromycin in Behcet’s disease. J Oral Pathol Med 34(1):13–16CrossRefPubMed

58.

Akman A, Kacaroglu H, Donmez L, Bacanli A, Alpsoy E (2007) Relationship between periodontal findings and Behcet’s disease: a controlled study. J Clin Periodontol 34(6):485–491. https://doi.org/10.1111/j.1600-051X.2007.01085.x CrossRefPubMed

59.

Mumcu G, Cimilli H, Karacayli U, Inanc N, Ture-Ozdemir F, Eksioglu-Demiralp E, Ergun T, Direskeneli H (2013) Salivary levels of HNP 1-3 are related to oral ulcer activity in Behcet’s disease. Int J Dermatol 52(10):1198–1201. https://doi.org/10.1111/j.1365-4632.2012.05504.x CrossRefPubMed

60.

Mumcu G, Cimilli H, Karacayli U, Inanc N, Ture-Ozdemir F, Eksioglu-Demiralp E, Ergun T, Direskeneli H (2012) Salivary levels of antimicrobial peptides Hnp 1-3, Ll-37 and S100 in Behcet’s disease. Arch Oral Biol 57(6):642–646. https://doi.org/10.1016/j.archoralbio.2011.11.003S0003-9969(11)00381-5 CrossRefPubMed

61.

Hatemi G, Yazici H (2011) Behcet’s syndrome and micro-organisms. Best Pract Res Clin Rheumatol 25(3):389–406. https://doi.org/10.1016/j.berh.2011.05.002 CrossRefPubMed

62.

Marta M, Santos E, Coutinho E, Silva AM, Correia J, Vasconcelos C, Giovannoni G (2015) The role of infections in Behcet disease and neuro-Behcet syndrome. Autoimmun Rev 14(7):609–615. https://doi.org/10.1016/j.autrev.2015.02.009 CrossRefPubMed

63.

The Behçet’s Disease Research Committee of Japan (1989) Skin hypersensitivity to streptococcal antigens and the induction of systemic symptoms by the antigens in Behçet’s disease–a multicenter study. J Rheumatol 16(4):506–511

64.

Tojo M, Zheng X, Yanagihori H, Oyama N, Takahashi K, Nakamura K, Kaneko F (2003) Detection of herpes virus genomes in skin lesions from patients with Behcet’s disease and other related inflammatory diseases. Acta Derm Venereol 83(2):124–127CrossRefPubMed

65.

Hatemi G, Bahar H, Uysal S, Mat C, Gogus F, Masatlioglu S, Altas K, Yazici H (2004) The pustular skin lesions in Behcet’s syndrome are not sterile. Ann Rheum Dis 63(11):1450–1452. https://doi.org/10.1136/ard.2003.017467 CrossRefPubMedPubMedCentral

66.

Fresko I, Yazici H, Bayramicli M, Yurdakul S, Mat C (1993) Effect of surgical cleaning of the skin on the pathergy phenomenon in Behcet’s syndrome. Ann Rheum Dis 52(8):619–620CrossRefPubMedPubMedCentral

67.

Forbes JD, Van Domselaar G, Bernstein CN (2016) The gut microbiota in immune-mediated inflammatory diseases. Front Microbiol 7:1081. https://doi.org/10.3389/fmicb.2016.01081 CrossRefPubMedPubMedCentral

68.

Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, Nielsen T, Pons N, Levenez F, Yamada T, Mende DR, Li J, Xu J, Li S, Li D, Cao J, Wang B, Liang H, Zheng H, Xie Y, Tap J, Lepage P, Bertalan M, Batto JM, Hansen T, Le Paslier D, Linneberg A, Nielsen HB, Pelletier E, Renault P, Sicheritz-Ponten T, Turner K, Zhu H, Yu C, Li S, Jian M, Zhou Y, Li Y, Zhang X, Li S, Qin N, Yang H, Wang J, Brunak S, Dore J, Guarner F, Kristiansen K, Pedersen O, Parkhill J, Weissenbach J, Meta HITC, Bork P, Ehrlich SD, Wang J (2010) A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464(7285):59–65. https://doi.org/10.1038/nature08821 CrossRefPubMedPubMedCentral

69.

Consolandi C, Turroni S, Emmi G, Severgnini M, Fiori J, Peano C, Biagi E, Grassi A, Rampelli S, Silvestri E, Centanni M, Cianchi F, Gotti R, Emmi L, Brigidi P, Bizzaro N, De Bellis G, Prisco D, Candela M, D’Elios MM (2015) Behcet’s syndrome patients exhibit specific microbiome signature. Autoimmun Rev 14(4):269–276. https://doi.org/10.1016/j.autrev.2014.11.009 CrossRefPubMed

70.

Shimizu J, Kubota T, Takada E, Takai K, Fujiwara N, Arimitsu N, Ueda Y, Wakisaka S, Suzuki T, Suzuki N (2016) Bifidobacteria abundance-featured gut microbiota compositional change in patients with Behcet’s disease. PLoS One 11(4):e0153746. https://doi.org/10.1371/journal.pone.0153746 CrossRefPubMedPubMedCentral

71.

Bik EM, Long CD, Armitage GC, Loomer P, Emerson J, Mongodin EF, Nelson KE, Gill SR, Fraser-Liggett CM, Relman DA (2010) Bacterial diversity in the oral cavity of 10 healthy individuals. ISME J 4(8):962–974. https://doi.org/10.1038/ismej.2010.30 CrossRefPubMed

72.

Cameron SJ, Huws SA, Hegarty MJ, Smith DP, Mur LA (2015) The human salivary microbiome exhibits temporal stability in bacterial diversity. FEMS Microbiol Ecol 91(9):fiv091. https://doi.org/10.1093/femsec/fiv091 CrossRefPubMed

73.

Seoudi N, Bergmeier LA, Drobniewski F, Paster B, Fortune F (2015) The oral mucosal and salivary microbial community of Behcet’s syndrome and recurrent aphthous stomatitis. J Oral Microbiol 7:27150. https://doi.org/10.3402/jom.v7.27150 CrossRefPubMed

74.

Ye Z, Zhang N, Wu C, Zhang X, Wang Q, Huang X, Du L, Cao Q, Tang J, Zhou C, Hou S, He Y, Xu Q, Xiong X, Kijlstra A, Qin N, Yang P (2018) A metagenomic study of the gut microbiome in Behcet’s disease. Microbiome 6(1):135. https://doi.org/10.1186/s40168-018-0520-6 CrossRefPubMedPubMedCentral

75.

Calguneri M, Ertenli I, Kiraz S, Erman M, Celik I (1996) Effect of prophylactic benzathine penicillin on mucocutaneous symptoms of Behcet’s disease. Dermatology 192(2):125–128. https://doi.org/10.1159/000246336 CrossRefPubMed

76.

Kaneko F, Oyama N, Nishibu A (1997) Streptococcal infection in the pathogenesis of Behcet’s disease and clinical effects of minocycline on the disease symptoms. Yonsei Med J 38(6):444–454. https://doi.org/10.3349/ymj.1997.38.6.444 CrossRefPubMed

77.

Mumcu G, Inanc N, Ozdemir FT, Tulunay A, Eksioglu-Demiralp E, Ergun T, Direskeneli H (2013) Effects of azithromycin on intracellular cytokine responses and mucocutaneous manifestations in Behcet’s disease. Int J Dermatol 52:1561–1566. https://doi.org/10.1111/ijd.12144 CrossRefPubMed

78.

Wagner EH, Austin BT, Davis C, Hindmarsh M, Schaefer J, Bonomi A (2001) Improving chronic illness care: translating evidence into action. Health Aff (Millwood) 20(6):64–78. https://doi.org/10.1377/hlthaff.20.6.64 CrossRef

Titel: Triggering agents and microbiome as environmental factors on Behçet’s syndrome
verfasst von: Gonca Mumcu
Haner Direskeneli
Publikationsdatum: 06.12.2018
Verlag: Springer International Publishing
Erschienen in: Internal and Emergency Medicine / Ausgabe 5/2019
Print ISSN: 1828-0447
Elektronische ISSN: 1970-9366
DOI: https://doi.org/10.1007/s11739-018-2000-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Bei Herzinsuffizienz muss „Eisenmangel“ neu definiert werden!

16.05.2024 Herzinsuffizienz Nachrichten

Bei chronischer Herzinsuffizienz macht es einem internationalen Expertenteam zufolge wenig Sinn, die Diagnose „Eisenmangel“ am Serumferritin festzumachen. Das Team schlägt vor, sich lieber an die Transferrinsättigung zu halten.

Herzinfarkt mit 85 – trotzdem noch intensive Lipidsenkung?

16.05.2024 Hypercholesterinämie Nachrichten

Profitieren nach einem akuten Myokardinfarkt auch Betroffene über 80 Jahre noch von einer intensiven Lipidsenkung zur Sekundärprävention? Um diese Frage zu beantworten, wurden jetzt Registerdaten aus Frankreich ausgewertet.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2019

Phenotypes in Behçet’s syndrome

Acute pericarditis or a systemic disease with pleuropulmonary involvement?

Long-term effectiveness and safety of switching from originator to biosimilar infliximab in patients with Behçet’s disease

From sadness to stiffness: the spleen’s progress

Early predictors for the diagnosis of liver abscess in the emergency department